Company profile · IDXX
IDEXX Laboratories, Inc.
Veterinary diagnostics and practice software
Exceptional Company Series · No. 4
Passes all five structural tests and clears our elevated bar on both the strength of the business today and the consistency of its earnings record. An assessment of business quality, not of the share price. About the series →
The one-minute version
IDEXX places diagnostic instruments in veterinary clinics at close to cost — the machine is the least profitable thing it sells. Every blood panel, urinalysis and rapid test the machine runs afterwards consumes IDEXX consumables, so 79% of revenue is recurring and scales with how often vets test, not with how many machines ship. The lock-in is the workflow: a clinic that retrains its staff around one system rarely switches. Earnings have compounded at 18.8% for twelve years, rising in 90% of comparisons — nine years in ten — on a worst drawdown of just 10%. That is what we mean by a structural compounder.
The five structural tests
Trajectory: mixed ↔ — 3 of 5 dimensions improved over the last 4 quarterly reports, 1 held, 1 weakened. Worth watching, not yet a concern.
The compounding record
The same five measures for every company in the series, so any two can be read against each other.
Why the economics are exceptional
The analyzer is the loss leader. IDEXX prices instrument placements to win the counter space in a veterinary practice, then earns its margin on everything that machine consumes for as long as it sits there. By the company's own FY2025 accounting, recurring revenue was 79% of the total.
The switching cost is a retrained workflow. A practice that adopts VetLab has retrained its technicians, built appointment flow around in-house turnaround times, and often wired results into IDEXX's cloud record system. Moving to a rival analyzer means re-training staff and re-plumbing software — friction most small practices have no appetite for.
A second, quieter moat. For tests a clinic cannot run itself, turnaround speed is the product, and speed is a function of laboratory density and courier logistics — infrastructure that takes years to build and is not undercut by a better analyzer alone.
The honest risk. Mars owns roughly 2,500 veterinary clinics and Antech, a rival diagnostics network. In every clinic Mars owns, the company choosing the equipment also owns a competitor — a structural conflict, not a hypothetical one.
Earnings, twelve years
The 2026 dip is 2020 — the only year it fell. The shape is the grade. Source: Legend, from company filings and market data, as at 21 August 2026.
Closing price, USD — not a valuation, not real-time. As of 2026-08-25.
Published 2026-08-25: Sells the analysers that sit in veterinary practices, then earns again on every test they run. The piece asks what makes that annuity durable.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Related force
- Precision Diagnostics & Testing Infrastructure
- Head office
- United States
- Employees
- 11,000
- Market cap (as of 2026-08-25)
- USD 44,135,829,504
- Return on equity (as of 2026-08-25)
- +74.2%
- P/E (trailing)
- 39.1×
- Profit margin
- 25.0%
- Beta (5y monthly, vs S&P 500)
- 1.54
- 52-week range
- 518.55 – 769.98 USD
- Website
- idexx.com
- Growth (YoY, market data)
- Revenue +9.7% · EPS +17.6%
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
New pieces go out by email
One company at a time, put through the same five structural tests. No trading alerts, no model portfolio, no urgency.
Subscribe on Substack →